Venmax Drugs & Pharmaceuticals Ltd will hold a meeting of its equity shareholders on October 24, 2026, to consider and approve the proposed merger with Hatri Pharma Private Limited. The meeting is scheduled at 12:30 pm (IST) and will be conducted through Video Conferencing or Other Audio Visual Means.

This development follows the order passed by the Hon'ble National Company Law Tribunal (NCLT), Hyderabad Bench-II, on September 7, 2026. The tribunal directed the convening of the meeting in relation to the Scheme of Arrangement involving the merger of Hatri Pharma Private Limited, the Transferor Company, into Venmax Drugs & Pharmaceuticals Limited, the Transferee Company.

Meeting details and access

The meeting will be held at the registered office of the Transferee Company in Hyderabad. Shareholders can access the Notice and Statement under Sections 230 and 232 read with Section 102 of the Companies Act, 2013, via the company website, the Bombay Stock Exchange website, and the CDSL e-voting portal.

The Notice is also being sent electronically to shareholders whose email addresses are registered with the company or depositories. The scheme is being executed under Section 230–232 and other applicable provisions of the Companies Act, 2013.

Venmax Drugs & Pharmaceuticals has been directed by the National Company Law Tribunal to convene an equity shareholder meeting regarding its proposed amalgamation with Hatri Pharma Private Limited. The tribunal issued the order on September 7, 2026, setting the stage for the next procedural step in the corporate restructuring process.

The National Company Law Tribunal, Hyderabad Bench, scheduled the meeting for Saturday, October 24, 2026, at 12:30 p.m. The session will be conducted through video conference or other audio-visual means, ensuring remote accessibility for shareholders. This directive follows the disposal of Case Application CA (CAA) 30/230/HDB/2026, which was heard before Judicial Member Rajeev Bhardwaj and Technical Member Sanjay Puri.

Scheme Details

The amalgamation falls under sections 230 to 232 of the Companies Act, 2013. Hatri Pharma Private Limited is designated as the amalgamating company, while Venmax Drugs serves as the amalgamated company. The tribunal’s order allows and disposes of the case application, mandating the convening of the shareholder meeting as a critical compliance step.

Venmax Drugs disclosed this development to the BSE Limited on September 8, 2026, citing SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company confirmed that the order copy and related documents are available on its official website for stakeholder reference.

What the Numbers Show

While no financial figures were disclosed in this specific regulatory filing, the progression to a shareholder vote indicates regulatory approval of the scheme’s structural validity. The timeline sets a clear deadline for investor engagement, with the October 24 meeting serving as the final approval gate before implementation.